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ABSTRACT
Idiopathic inÀ ammatory myopathies (IIM), which include dermatomyositis (DM) and polymyositis (PM), are chronic 
systemic diseases associated with high morbidity and functional disability. Current treatment is based on the use of 
glucocorticoids and immunosuppressive drugs, but a considerable number of patients is refractory to traditional therapy. 
That has led to the attempted use of biologics based on the physiopathogenesis of IIM. From the immunopathological 
viewpoint, PM and DM differ: the former is more related to cellular immunity, while the latter, to humoral immunity. In 
both, however, elevated concentrations of proinÀ ammatory interleukins (TNF, IL-1, IL-6) and increased expression of 
molecules related to costimulation of T lymphocytes have been described; thus, the use of biologics in those conditions 
seems reasonable. Considering the biologics available, open-label studies are scarce, comprising mainly case reports 
and series. TNF blockers have yielded conÀ icting results, with no evidence of good response to treatment. The anti-
CD20 therapy has the most promising results. Data on T lymphocyte costimulation blockade and anti-IL-6 therapy are 
extremely scarce, preventing any consideration. Thus, the use of biologics in IIM still remains an unconquered frontier. 
Biologics may have an important role in the management of IIM refractory to conventional therapy, but further prospec-
tive studies based on objective parameters of response to treatment are needed. So far, anti-CD20 therapy seems to be 
the most promising treatment for refractory IIM. 
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INTRODUCTION
Dermatomyositis (DM) and polymyositis (PM) are part of the 
idiopathic inÀ ammatory myopathies (IIM), a heterogeneous 
group of chronic systemic autoimmune myopathies, associ-
ated with high morbidity and functional disability. Each has 
different epidemiological, histological, immunohistochemical, 
pathological, and clinical characteristics, as well as different 
disease courses.
Being uncommon diseases, drug therapy for DM and 
PM is mainly based on case reports or series. In general, 
corticosteroids have been recommended as ¿ rst-line drugs, and, 
as corticosteroid-sparing agents, several immunosuppressive 
drugs. However, a signi¿ cant number of patients do not respond 
satisfactorily to those traditional treatments. In such cases, bio-
logics are used based on the physiopathology of DM and PM.
MATERIALS AND METHODS
A systematic review of the articles available in the literature 
was performed, including articles published up to January 
2012. The review was based on a bibliographic search in 
the Medical Literature Analysis and Retrieval System online 
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(MEDLINE) database. The following terms were assessed: der-
matomyositis, biologics, immunobiologicals, immunopathology, 
polymyositis, drug therapy, and treatment.
Immunopathology
Polymyositis is characterized by an in¿ ltrate of CD8+ T lym-
phocytes and macrophages in muscle ¿ bers, which express 
increased MHC class I antigen levels1 and release perforin 
granules, resulting in lysis of the muscle ¿ bers.2 In DM, B 
lymphocytes play a relevant role in the disease pathogenesis 
due to the presence of autoantibodies, the deposition of im-
mune complexes in the dermal-epidermal junction of skin 
lesions, and the presence of B lymphocytes around inÀ amed 
muscle ¿ bers3,4 and perivascular areas.5,6
Cytokines and chemokines
Cytokines and chemokines produced by muscle ¿ bers, and 
inÀ ammatory and endothelial cells can contribute to the 
pathogenesis of myopathies. ProinÀ ammatory cytokines, 
such as interleukins 1Į (IL-1 Į) and IL-1 ȕ, tumor necrosis 
factor Į (TNF-Į), interferons Į and ȕ (IFN-Į and INF-ȕ), 
and high-mobility group protein B1 (HMGB1), in addition to 
chemokines [such as Į-chemokines (CXCL9 CXCL10) and 
ȕ chemokines (CCL2, CCL3, CCl4, CCL19, CCL21)], are 
present in the muscle tissue of patients with DM and PM.3í6
Other cytokines, such as IL-15 and IL-18, have been 
recently described, suggesting they might play a role in 
the pathogenesis and activity of myositis, requiring further 
studies.7í12 
The treatment of the myopathies refractory to conven-
tional treatment might, at least theoretically, be targeted at 
blocking those cytokines and chemokines. 
Tumor necrosis factor 
The TNF has been correlated with the pathogenesis of IIM.8í12 
Using immunohistochemistry and in situ hybridization, Kuru 
et al.8 have shown that muscle ¿ bers of patients with DM 
and PM express and synthesize TNF, while Lundberg et al.9 
have shown increased levels of messenger RNA (mRNA) of 
TNF in muscle biopsies. Shimizu et al.12 have found increased 
serum levels of soluble TNF receptors in DM and PM. The 
levels of other cytokines, such as TNF ȕ, IL-1Į, IL-1ȕ, IL-2 
and IFN-Ȗ, are also increased in muscle biopsies of patients 
with DM and PM, contributing to the local inÀ ammation 
cascade.8í15
It is worth noting that TNF, IL-1 and IFN induce the ex-
pression of MHC class I antigen by muscle ¿ bers,1 and both 
regulate muscle metabolism and regeneration.15
Interleukin 1 
Muscle weakness has been suggested not to correlate with 
the presence of inÀ ammatory cell in¿ ltrates; however, the 
presence of IL-1 detected in endothelial cells of patients with 
muscle weakness and no inÀ ammatory cell in¿ ltrate suggests 
the participation of proinÀ ammatory interleukins.16,17 TNF 
has catabolic effects and works together with IL-1, leading 
to skeletal muscle mass loss.18 The increased expression of 
IL-1 (IL-1 Į, IL-1 ȕ, IL-1 Ra), on its turn, correlates with the 
increase in IL-1 receptor in muscle ¿ bers,19 intensifying the 
immune mechanism of myositis.
IL-1Į, which is markedly expressed in the muscle tissue 
of patients with myositis, can stimulate the production of 
prostaglandin E2 (PGE2) in skeletal muscle.19
Interleukin 6 
The serum levels of IL-6 are also elevated and correlate with 
the activity of DM.20 An increase was observed in the expres-
sion of mRNA of IL-6 in muscle tissues of patients with PM 
and DM, but not in normal muscles.20 Okiyama et al.21 have 
shown that IL-6 is expressed in macrophages in¿ ltrating 
muscle tissues, and that the administration of monoclonal 
anti-IL-6 receptor antibodies prevented the appearance and 
progression of the inÀ ammatory myopathy.
Interferon 
In the muscle tissue and peripheral blood of patients with DM 
and PM, IFN gene expression has been observed and can be 
associated with disease activity.22,23
Interferon activates natural killer cell cytotoxicity, pro-
motes T lymphocyte  activation and survival, and dendritic 
cell maturation,22,23 in addition to enhancing MHC class I ex-
pression by muscle ¿ bers.1 On the other hand, IFN-regulated 
proteins (IP-10, I-TAC, MCP-1 and MCP-2) are elevated and 
play a role in recruiting lymphocytes for muscle inÀ amma-
tion sites.24
The fact that the muscle ¿ bers of patients with IIM ex-
press MHC class I antigens implicates that such ¿ bers might 
behave as antigen-presenting cells for CD8+ T lymphocytes. 
Based on that hypothesis, Murata et al.25 have shown that 
muscle ¿ bers of patients with PM also express the costimu-
latory molecule BB-1. On the other hand, CD8+ T lym-
phocytes around those ¿ bers expressed CD28 and CTLA-4 
(CD152). Behrens et al.26 have reported that muscle ¿ bers 
expressed BB-1 after stimulation with either IFN-Ȗ or TNF-Į.
The use of biologics is supported by those immunopatho-
logical ¿ ndings, particularly in cases of IIM refractory to 
corticosteroids and several immunosuppressive drugs.
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Immunotherapy/Immunobiologics
Anti-TNF therapy
Inﬂ iximab
InÀ iximab is a chimeric monoclonal antibody against TNF-Į, 
composed by a sequence of peptides, 75% human and 25% 
murine.27
Some reports have shown an improvement in the muscle 
strength of patients with IIM, and a reduction in the serum 
levels of muscle enzymes after the treatment with biologics 
of the anti-TNF-Į type.27í38 However, results are not homo-
geneous. Efthimiou et al.39 have published a retrospective 
study with 2 patients with DM refractory to conventional 
treatment (methotrexate and azathioprine). One of the 
patients had previously used etanercept and intravenous 
human immunoglobulin, with no change in the myopathic 
¿ ndings. Both patients were treated with inÀ iximab at the 
dose of 3 mg/kg at intervals similar to those recommended 
for rheumatoid arthritis. After a mean follow-up of 15.2 
months, the patients showed no signi¿ cant reduction in the 
serum levels of creatine kinase, and only one of them showed 
a mild improvement in muscle strength within the ¿ rst three 
months of treatment. However, the results of an open-label 
study with inÀ iximab as the ¿ rst treatment option, published 
by Hengstamn et al.34 and using a dose of 10 mg/kg of 
weight associated with methotrexate, at intervals of 0, 2, 6, 
22, 38 and 46 weeks, have not been conclusive due to the 
high relapse rate and dif¿ culty to include cases, leading to 
an early end of the study. Another open-label pilot study 
of inÀ iximab in 13 patients with refractory inÀ ammatory 
myopathies (5 with PM; 4 with DM; and 4 with inclusion 
body myositis) used methotrexate as the immunosuppressive 
agent. The inÀ iximab dose used was 5 mg/kg of body weight 
at weeks 0, 2, 6 and 14. Four patients discontinued the study 
(3 due to adverse events and 1 due to the presence of ovarian 
malignancy). Of the 9 patients completing the study, only 3 
had at least a 20% improvement in 3 or more International 
Myositis Assessment and Clinical Studies Group (IMACS) 
variables (disease activity score).35
Adalimumab
Adalimumab is a fully human monoclonal antibody that 
blocks the TNF-Į molecule directly.40
The use of adalimumab for systemic autoimmune diseas-
es, mainly rheumatoid arthritis, can induce the development 
of inÀ ammatory myopathies (all descriptions were DM).40í46 
That is probably the reason why, due to fear of exacerbating 
the inÀ ammatory myopathy, there is no description of the 
use of adalimumab as drug therapy for patients with either 
PM or DM. 
Etanercept
Etanercept is a soluble recombinant TNFĮ receptor, composed 
of a dimeric fusion protein with a constant region of human 
IgG1 and variable regions of murine antibody.47
Iannone et al.38 have reported 5 patients with DM refrac-
tory to corticotherapy and to immunosuppressive agents 
(combination of methotrexate and azathioprine), who re-
ceived etanercept subcutaneously (25 mg, 2x/week) for a 
minimum of 3 months. The patients showed no improvement 
in the cutaneous ¿ ndings, worsened their muscle weakness, 
and increased their serum levels of muscle enzymes.
Sprott et al.37 have reported the case of a patient with 
PM refractory to conventional drug treatment (methotrexate, 
azathioprine and/or intravenous human immunoglobulin in 
association with corticosteroids). Because of disease re-
fractoriness, etanercept (25 mg, 2 x/week, subcutaneously) 
was initiated, and corticotherapy was later suspended due to 
stability of the clinical and laboratory ¿ ndings.
Efthimiou et al.39 have reported the cases of 8 patients 
(3 with DM) refractory to methotrexate, azathioprine and 
intravenous human immunoglobulin, who underwent ad-
junct therapy with etanercept and/or inÀ iximab; 6 patients 
responded. Of those 8 patients, 6 received etanercept (25 mg, 
2 x/week), 1 receives inÀ iximab and 1 received sequential 
therapy with 2 agents. The problem with that report is the 
concomitance of therapies, which can be a confounding factor 
in the improvement reported. Six of the 8 patients studied 
underwent monthly pulse therapy with methylprednisolone, 
and all of them received intravenous human immunoglobulin 
(2 g/kg of body weight) associated with etanercept.
Rituximab
Rituximab is a chimeric monoclonal antibody directed against 
CD20 antigen present on the surface of B cells. Its administra-
tion leads to the selective depletion of CD20+ B lymphocytes. 
Recently rituximab has been used for refractory DM and 
PM,7,48í56 considering the important role of B and T lympho-
cytes in mediating IIM activity.57í60 However, the ef¿ cacy of 
rituximab in the treatment of PM7,55,56 contradicts the models 
proposed for the disease pathogenesis, because the depletion 
of B lymphocytes in PM leads to a satisfactory clinical and 
laboratory response. In the case of PM, the predominance of 
the cytotoxic CD8+ T lymphocytic in¿ ltrate in muscles6,57,60 
suggests a more important role of B lymphocytes in the 
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pathogenesis of PM than previously recognized, acting as 
costimulatory or antigen presenting cells.
In 2005, a small open-label study with rituximab 
(100 mg/m2 for 4 weeks) was performed with 6 patients 
with DM refractory to conventional drug treatment (1 had 
no previous drug treatment and 1 was refractory to previ-
ous use of etanercept).48 Improvement was observed in 
muscle strength, muscle enzymes and skin lesions, with a 
peak improvement in muscle strength after 12 to 36 weeks 
of treatment. All patients had depletion of B lymphocytes. 
Four patients experienced a return of symptoms that coin-
cided with the return of B lymphocytes. Other parameters, 
including rash, alopecia and reduced forced vital capacity, 
improved. Chung et al.50 treated 8 patients with DM refrac-
tory to multiple immunosuppressive drugs, one of whom 
after etanercept failure, with 2 infusions of rituximab (1 g 
each, 2 weeks apart). Three patients had improvement of 
their muscle strength, but signi¿ cant change was observed 
in neither the levels of muscle enzymes nor the severity of 
skin lesions after 24 weeks of drug infusion.
In 2005, Lambotte et al.55 reported the case of a patient 
with PM, whose clinical and laboratory ¿ ndings improved 
after receiving rituximab (375 mg/m2/week for 4 weeks).
Another study has reported the treatment with rituximab 
(375 mg/m2/week for 4 weeks) of 4 other patients with PM 
refractory to corticosteroids and methotrexate»azathioprine. 
In analysis of 28 weeks of medication, all patients improved 
their muscle strength, and 2 achieved normal strength. The 
creatine kinase level normalized and the corticosteroid dose 
was reduced in all cases.56 
Tocilizumab
Tocilizumab is a humanized monoclonal anti-IL-6 antibody. 
The only study in the literature61 describes 2 male patients 
diagnosed with PM, both positive for anti-Jo-1 antibody. 
One patient, refractory to corticosteroid (1 mg/kg/day), 
azathioprine (100 mg/day) and cyclosporine (100í150 mg/
day), received tocilizumab (8 mg/kg, monthly, intravenous). 
After 1 year using the drug, corticosteroid was suspended, 
and cyclosporine (100 mg/day) maintained. There was 
evidence of progressive improvement in the muscle strength 
and laboratory ¿ ndings. The other patient was refractory to 
corticosteroid (1 mg/kg/day), azathioprine, cyclosporine and/
or methotrexate. Initially he received tocilizumab monthly 
(8 mg/kg, intravenous), and after the forth dose, the interval 
was reduced to 3 weeks. After 12 cycles of tocilizumab, as-
sociated with methotrexate, the patient showed stability of 
the clinical and laboratory ¿ ndings.
Abatacept
Abatacept is a human recombinant fusion protein, contain-
ing the extracellular domain of CTLA-4, which binds to the 
CD 80/86 receptor of an antigen-presenting cell. That interac-
tion blocks the activation of the CD 28 receptor in T cells.62
Literature review shows only one case report63 of a 
51-year-old female patient with PM refractory to corticoste-
roid and methotrexate/azathioprine, who received abatacept 
(750 mg intravenously, monthly). Her clinical and laboratory 
¿ ndings improved at the beginning of treatment, with nor-
malization of the creatine kinase, aldolase and lactic dehy-
drogenase levels 3 months after beginning the applications. 
The response persists after 3 years of follow-up. 
FINAL CONSIDERATIONS
The use of biologics for patients with DM and PM remains 
an unconquered frontier. The literature review yielded a few 
articles, comprising small non-controlled studies, mainly case 
reports and series. The TNF blocking agents have conÀ ict-
ing results. In addition, development of IIM during their use 
have been reported. So far, the most encouraging evidence 
originates from the anti-CD20 therapy with satisfactory re-
sults reported, but still requiring further investigation. The 
IL-6 inhibition and costimulation blockade in IIM have been 
only anecdotally reported, and, so far, no conclusion has been 
extracted from them. 
Thus, biologics might play a relevant role in the manage-
ment of IIM refractory to conventional therapy. However, 
evidence justifying that approach might only be produced by 
use of new prospective studies based on objective parameters 
of response to treatment. So far, anti-CD20 therapy seems to 
be the most promising treatment for refractory IIM.
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in¿ ltrado de linfócitos T CD8+ citotóxicos nos músculos6,57,60 
sugere papel mais importante para os linfócitos B na patogê-
nese da PM anteriormente reconhecida, atuando talvez como 
coestimulador ou apresentador de antígenos.
Em 2005, foi realizado pequeno estudo aberto com ri-
tuximabe (100 mg/m2 por 4 semanas) em 6 pacientes com 
DM refratários ao tratamento medicamentoso convencional, 
sendo 1 desses sem tratamento medicamentoso prévio e 1 
refratário ao uso preliminar de etanercepte.48 Houve melhora 
de força muscular, enzimas musculares, lesões cutâneas, 
com pico de melhora da força muscular após 12 a 36 se-
manas de tratamento. Os linfócitos B foram depletados em 
todos os pacientes. Em 4 casos, a recidiva dos sintomas 
correlacionou-se ao retorno de linfócitos B. Houve melhora 
de outros parâmetros, incluindo rash, alopecia e capacidade 
vital forçada. Chung et al.50 trataram 8 pacientes com DM 
refratários a múltiplos imunossupressores, 1 deles após 
falha com etanercepte, com 2 infusões de rituximabe (1 g 
com intervalo de 2 semanas). Três apresentaram melhora da 
força muscular, mas não  houve mudança signi¿ cativa das 
enzimas musculares e da graduação de lesões cutâneas após 
24 semanas de infusão da droga.
Em 2005, Lambotte et al.55 relataram caso de PM que teve 
melhora clinicolaboratorial com a aplicação de rituximabe 
(375 mg/m2/semana por 4 semanas).
O tratamento (375 mg/m2/semana por 4 semanas) de ou-
tros 4 casos de pacientes com PM, que falharam ao tratamento 
com corticosteroide e metotrexato»azatioprina, foi relatado. 
Em análise de 28 semanas após uso da medicação, todos os 
pacientes apresentaram melhora da força muscular, com 2 
casos atingindo força normal. O nível de creatinoquinase 
normalizou e a dose de corticosteroide foi reduzida em todos 
os os casos.56
Tocilizumabe
É um anticorpo monoclonal humanizado anti-IL-6. O único 
relato de caso na literatura 61 descreve 2 pacientes do gênero 
masculino com diagnóstico de PM, ambos com anticorpo 
anti-Jo-1 positivo. O primeiro, refratário a corticosteroide 
(1 mg/kg/dia), azatioprina (100 mg/dia) e ciclosporina 
(100í150 mg/dia), recebeu tocilizumabe (8 mg/kg, mensal, 
intravenosa). Após cerca de 1 ano de uso da medicação, o 
corticosteroide foi suspenso e mantido ciclosporina (100 mg/
dia), com evidência de melhora progressiva da força muscular 
e do per¿ l laboratorial. O segundo paciente foi refratário a 
corticoterapia (1 mg/kg/dia), azatioprina, ciclosporina e/ou 
metotrexato. Recebeu inicialmente tocilizumabe (8 mg/kg, 
mensal, intravenoso), com redução do intervalo para 3 em 
3 semanas após a 4ª dose. Após 12 ciclos de tocilizuma-
be, associado ao uso de metotrexato, houve estabilidade 
clinicolaboratorial.
Abatacepte
O abatacepte é uma proteína de fusão humana recombinante 
que contém o domínio extracelular do CTLA-4, que se liga 
ao receptor CD 80/86 de uma célula apresentadora de antí-
geno. Essa interação bloqueia a ativação do receptor CD 28 
na célula T.62
A revisão da literatura revela apenas 1 relato de caso63 de 
paciente do gênero feminino, de 51 anos, com PM refratária 
à corticosteroide e a metotrexato/azatioprina, que recebeu 
abatacepte (750 mg mensal intravenosa). Houve melhora clini-
colaboratorial logo ao início do tratamento, com normalização 
da creatinoquinase, aldolase e desidrogenase láctica passados 
3 meses do início das aplicações, com manutenção de resposta 
em 3 anos de seguimento. 
CONSIDERAÇÕES FINAIS
Dessa maneira, o uso de imunobiológicos em casos de DM e 
PM ainda permanece como fronteira a ser explorada. A revi-
são da literatura se mostra escassa, com trabalhos pequenos e 
não controlados, formados principalmente por relatos e séries 
de casos. Os agentes bloqueadores de TNF têm resultados 
conÀ itantes, e há relatos de desenvolvimento de MII durante 
o uso desses fármacos. As evidências mais animadoras, até o 
momento, vêm da terapia anti-CD-20, com resultados satis-
fatórios nos trabalhos existentes, mas ainda necessitando de 
investigação mais criteriosa. A inibição da IL-6 e o bloqueio 
da coestimulação nas MII apresentam apenas raros relatos 
anedóticos, dos quais, por enquanto, não é possível tirar 
qualquer conclusão. 
Assim, a terapia biológica pode ter papel relevante no 
tratamento das MII refratárias à terapia convencional; no 
entanto, somente com novos estudos prospectivos com base 
em parâmetros objetivos de resposta ao tratamento poder௘-se-á 
produzir evidências que justi¿ quem essa conduta. Até o presen-
te momento, a terapia anti-CD20 parece ser a mais promissora 
no tratamento das MII refratárias.
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